Related Experiment Video
Updated: Jul 5, 2026
13:32
High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
Antegren Athena Neurosciences Inc
1Cytel Corporation, 3525 John Hopkins Court, San Diego, CA 92121, USA. Mariano_elices@cytelcorp.com
Idrugs : the Investigational Drugs Journal
|May 10, 2008
Summary
Antegrin, a monoclonal antibody targeting alpha4beta1 integrin, shows promise in treating multiple sclerosis by significantly reducing new brain lesions. It was also well-tolerated and effective in pilot studies for Crohn's disease and ulcerative colitis.
Area of Science:
- Immunology
- Neuroscience
- Gastroenterology
Background:
- Alpha4beta1 integrin (VLA-4) on leukocytes binds VCAM-1 on brain endothelial cells, mediating autoimmune disorders like multiple sclerosis (MS).
- Antegrin (AN-100226) is a humanized monoclonal antibody targeting VLA-4, developed for MS exacerbations.
Purpose of the Study:
- To evaluate the efficacy and safety of Antegrin in treating multiple sclerosis exacerbations.
- To assess Antegrin's potential in managing Crohn's disease and ulcerative colitis.
Main Methods:
- Phase II clinical trials involving 70 MS patients over 12 weeks.
- Pilot studies with 40 patients diagnosed with Crohn's disease or ulcerative colitis.
Main Results:
- Antegrin significantly reduced new brain lesions in multiple sclerosis patients.
- Treatment with Antegrin demonstrated good tolerability and efficacy in pilot studies for inflammatory bowel diseases.
Conclusions:
- Antegrin shows significant therapeutic potential for multiple sclerosis exacerbations.
- Antegrin is a promising treatment option for inflammatory bowel diseases, warranting further investigation.
